Freedom to Heal Act of 2025

The Freedom to Heal Act of 2025 (S.3346), introduced by Senator Booker (D-NJ) with two cosponsors, was read twice and referred to the Senate Committee on the Judiciary on December 4, 2025. An identical companion bill, H.R.6434, has also been introduced in the House. The bill aims to establish a special registration process for physicians to administer Schedule I investigational drugs to eligible patients under the Federal Right to Try law. This legislation does not authorize or appropriate any specific funding. Instead, it creates a regulatory mechanism by amending the Controlled Substances Act to allow for the direct administration of certain investigational drugs. The financial impact would primarily stem from potential changes in the operational landscape for pharmaceutical companies developing Schedule I investigational drugs and healthcare providers involved in 'Right to Try' programs. There is no direct money trail from the government to specific companies or sectors outlined in the bill. Structural winners could include pharmaceutical companies developing Schedule I drugs for serious conditions, as this legislation could streamline access for eligible patients, potentially accelerating data collection or market understanding for these therapies. However, without specific companies or drugs named, and given the early stage of the bill, no specific tickers can be identified as direct beneficiaries at this time. The bill's focus is on regulatory relief rather than direct financial incentives. As of April 7, 2026, the bill remains in the early procedural phase, having only been referred to committee in both chambers. The next legislative steps would involve committee hearings, potential markups, and a vote in the Judiciary Committee before it could advance to the full Senate. The existence of a companion bill in the House indicates bipartisan and bicameral interest, which could increase its probability of passage compared to a standalone bill.